Preface. Early phase dose finding methodology

DOI10.1002/SIM.7155MaRDI QIDQ7002170zbMATH OpenFDO

Authors

Publication date 4 April 2025

Published in Statistics in Medicine (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1002/SIM.7155

Mathematics Subject Classification ID

Proceedings of conferences of miscellaneous specific interest (00B25) Proceedings, conferences, collections, etc. pertaining to statistics (62-06) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials
• A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials
• Designs for phase I trials in ordered groups
• Identifying a maximum tolerated contour in two-dimensional dose finding
• Implementation of adaptive methods in early-phase clinical trials
• Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration
• Performance of toxicity probability interval based designs in contrast to the continual reassessment method
• Sequential monitoring of phase I dose expansion cohorts

This page was built for publication: Preface. Early phase dose finding methodology

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q7002170)